Ownership and insider activity for Soligenix, Inc. (SNGX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions.
Price
| Price | $0.36 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2025-12-11 | Straube Richard | A-Award | 10,000 | $16K |
| 2025-12-11 | Donini Oreola | A-Award | 100,000 | $163K |
| 2025-12-11 | Guarino Jonathan L. | A-Award | 100,000 | $163K |
| 2025-12-11 | SCHABER CHRISTOPHER J | A-Award | 200,000 | $326K |
| 2025-10-02 | SCHABER CHRISTOPHER J | P-Purchase | 15,132 | $20K |
| 2025-06-20 | LAPOINTE ANTHONY GREGG | A-Award | 17,647 | $30K |
| 2025-06-20 | ZELDIS JEROME B | A-Award | 17,647 | $30K |
| 2025-06-20 | RUBIN ROBERT J. | A-Award | 17,647 | $30K |
| 2025-06-20 | Parks Diane L. | A-Award | 17,647 | $30K |
| 2024-12-12 | Parks Diane L. | A-Award | 8,646 | $30K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.8M | $7.8M | $9.0M | $5.4M | $18.7M | $26.0M | $13.4M | $8.4M | $7.8M | $7.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $1.2M | $1.3M | $1.2M | $1.5M | $564870 | $242721 | $219328 | $195148 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $10.1M | $9.4M | $10.3M | $7.5M | $19.5M | $26.6M | $13.9M | $9.5M | $8.8M | $8.8M |
| Property, Plant & Equipment | $26702 | $37163 | $19634 | $161505 | $251537 | $128375 | $359468 | $241761 | $115076 | $354965 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $126628 | $73952 | $46863 | $19699 | $23250 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $10.3M | $9.5M | $10.5M | $7.8M | $19.9M | $26.9M | $14.3M | $9.8M | $9.0M | $9.2M |
| Accounts Payable | $1.7M | $1.8M | $2.1M | $2.7M | $2.1M | $2.9M | $3.9M | $1.1M | $667896 | $1.1M |
| Short-term Debt | 0 | 0 | 0 | 0 | $324979 | 0 | $9.9M | $2.2M | $1.4M | 0 |
| Total Current Liabilities | $2.9M | $3.2M | $4.2M | $6.3M | $6.1M | $6.3M | $16.5M | $6.2M | $4.8M | $3.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | $10.0M | $9.9M | 0 | $1.0M | 0 | 0 |
| Total Liabilities | $2.9M | $3.2M | $4.2M | $6.3M | $16.1M | $16.1M | $16.8M | $7.3M | $4.8M | $3.9M |
| Retained Earnings | -$150.1M | -$157.3M | -$166.2M | -$175.5M | -$193.2M | -$205.8M | -$219.6M | -$225.7M | -$234.0M | -$245.1M |
| Total Equity | $7.4M | $6.3M | $6.3M | $1.5M | $3.7M | $10.7M | -$2.5M | $2.5M | $4.1M | $5.3M |
| Total Debt | 0 | 0 | 0 | $127224 | $10.5M | $10.0M | $10.2M | $3.5M | $1.5M | $358144 |
| Net Debt | -$8.8M | -$7.8M | -$9.0M | -$5.3M | -$8.2M | -$16.1M | -$3.1M | -$5.0M | -$6.3M | -$7.6M |
| Working Capital | $7.2M | $6.2M | $6.1M | $1.2M | $13.4M | $20.3M | -$2.7M | $3.4M | $4.0M | $5.1M |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 2.77 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -39.65 |
Profitability
| Return on Equity | -181.02% |
| Return on Invested Capital | -151.39% |
| Return on Assets | -97.52% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CANF · CMND · ENSC · KZIA · OGEN · QLGN · SILO
Explore sector: Healthcare · Biotechnology
More sections of SNGX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks